{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"97.5","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"97.5","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"52.2","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"70.8","value":"0.0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"97.5","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"description":"CR Rate was assessed by the investigator per 2017 European Leukemia Net (ELN) Response Criteria for Acute Myeloid Leukemia (AML) and was defined as bone marrow blasts \\<5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count (ANC) ≥1.0 × 10\\^9/L (1000/µL); and platelet count ≥100 × 10\\^9/L (100,000/µL). The percentage of participants with CR (CR Rate) was reported for each arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were to receive 7.5 mg of MK-0482 via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks \\[Q3W\\]) for up to 35 cycles (approximately 24 months).","id":"OG000","title":"MK-0482 7.5 mg Q3W"},{"description":"Participants were to receive 25 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG001","title":"MK-0482 25 mg Q3W"},{"description":"Participants were to receive 75 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG002","title":"MK-0482 75 mg Q3W"},{"description":"Participants were to receive 225 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG003","title":"MK-0482 225 mg Q3W"},{"description":"Participants were to receive 750 mg of MK-0482 via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 24 months).","id":"OG004","title":"MK-0482 750 mg Q3W"}],"paramType":"NUMBER","populationDescription":"All allocated participants who received at least 1 dose of study intervention and had a baseline assessment were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to approximately 10 months","title":"Complete Remission (CR) Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}